Fig. 4

Requirement of CD4 + and CD8 + T cells for tumor rejection
Mice were immunized once subcutaneously with 2.5 × 106 embryonic fibroblasts expressing MAGE-1 (EF-MAGE-1) or intramuscularly with 100 µg of plasmid pCMV-MAGE-1 and injected 2 weeks later with 1.5 × 106 B16-MAGE-1 cells. Wild type: normal C57BL/6 mice; CD4−/−; CD4-deficient C57BL/6 mice; CD8−/−: CD8-deficient C57BL/6 mice.